These results are indicative of a model in which redundancy in granzymes facilitates killing against leukemias/lymphomas with low Fas expression whereas redundancy between GZMB and FasL facilitates killing of solid tumor targets with high Fas expression. This evidence concerns the gene FAS and lymphoma.